September 27, 2024

Dundee, Scotland, September 27, 2024 – Tay Therapeutics (“Tay”) today announced the publication of a composition of matter patent, WO2024194607, entitled “Pyrimido [4,5-B][1,5]naphthyridine-4,5(3H,10H)-dione derivatives for the treatment of diseases associated with PTC mutations, such as e.g. Cancer”, with the United Kingdom Intellectual Property Office (IPO) under the Patent Cooperation Treaty (PCT).

This new patent covers a proprietary class of Readthrough agents developed by Tay Therapeutics to address high-value opportunities in genetic diseases and certain cancers, including recessive dystrophic epidermolysis bullosa (RDEB). This intellectual property milestone reinforces Tay’s strategy to expand its therapeutic pipeline and enhance market opportunities through strategic partnerships and potential licensing deals.

“The publication of this patent strengthens Tay’s intellectual property portfolio and highlights our commitment to developing therapies for unmet needs,” said Andrew Woodland, CEO, Tay Therapeutics. “We are excited about the potential of our first-in-class Readthrough agents to transform treatment paradigms for severe genetic diseases and selected cancers.” This patent not only expands Tay’s intellectual property estate but also strengthens our positioning for future collaborations and commercial transactions in the biotech sector.”

For more information and partnership opportunities, get in touch with us.